RNA Leaders

??RNA Leaders Industry News ?? ? Happy Rare Disease Day 2025! ? Hear from industry experts how RNA-based therapeutics targeting rare diseases are evolving, at RNA Leaders Europe 2025 next week! (4-6th March, Basel).. ??Keynote Panel: RNA Partnerships of Big Pharma, Biotech, Industry Providers ?? Alexander Zehnder, MD, MBA, CureVac ?? Ulrik Lytt Rahbek, Novo Nordisk ?? Malgorzata Gonciarz, Novartis ?? John D. Taylor, Ribocure Pharmaceuticals AB ?? Renee T. Williams, PhD MBA ??Keynote Panel: Investment in Nucleic Acid Therapeutics and Enabling Technologies ?? Paola Pozzi, Sofinnova Partners ?? Michael Kyriakides, Syncona Limited ?? Kristin Thompson, Merieux Equity Partners ?? Adrien C., AdBio partners ?? Marianne Mertens, Apollo Health Ventures ?? Siham Ceballos PhD MBA, BioArtemis ?? Keynote Panel: Addressing Delivery Tools Needed to Support Next-Gen RNA Therapeutics ?? Aurelie Govenvalle, INSERM ?? Richard Klar, Secarna Pharmaceuticals ?? Toma? Einfalt, Novartis ??Shalini Andersson, AstraZeneca ??Lisa Melton, Nature Magazine ??Keynote Panel: Future of RNA Therapeutics & Diagnostics ?? Paul Nioi, Alnylam Pharmaceuticals ??Dr. Myriam Mendila, CureVac ?? Michelle Lynn Hall, Eli Lilly and Company ??Hendrik Knoetgen, Roche ??Dan Staner. ALCEDIAG ??Sonja Merkas, PhD, Livinovea – Life Science Consultancy ?? Confirm your place in Basel here: https://lnkd.in/d5j_TVPj #RNALeaders #rarediseaseday #RNA

?????????? ???? ???????? ?????????????? ??????!? On Rare Disease Day, we recognise the scientific community working to change the futures of millions living with rare diseases. RNA Leaders Europe, explores how RNA-based advances are leading the way for rare disease breakthroughs, including: ??Expanding RNA Beyond Infectious Diseases – Exploring how Big Pharma, Biotech, and Industry Providers are tackling neurological, cardiovascular, respiratory, and rare diseases. ??Endless RNA for Multi-Disease Targets – Sail Biomedicines is leading the charge with AI-designed endless RNA (eRNA) and programmable nanoparticles, unlocking long-lasting therapies for rare diseases, cancer, metabolic disorders, and more. ??mRNA Therapy for Argininosuccinic Aciduria - UCL is pioneering a breakthrough mRNA-based treatment to correct glutathione metabolism in this rare condition. RNA is redefining the possibilities of medicine. Join us in this exciting journey. Find out more here https://lnkd.in/d9upXH2t

?????????? ???????????????????????? – ?????? ?????????????? ????????????! Acquisitions, Partnerships, and Lessons Learned! Novo Nordisk and NanoVation Therapeutics? share their insights on lessons learned from 2024 and how 2025 will look in our Keynote Fireside Chat. The session will cover: ??Insights into Novo Nordisk’s recent acquisition and collaborations in RNA therapeutics ??Deep dive into the Pharma and Biotech views throughout the partnership process? ??Life after the acquisition, including lessons learnt and new working dynamics and considerations Who else will be joining us next week? Download the attendee list - ?? https://lnkd.in/efMgyYmy Register here - ??https://lnkd.in/evq5uCb2 #RNALEADERS #BIOTECH #RNA #RNAtherapeutics #mRNA #tRNA #Oligo #tissuetargeting #pharma #rnadeals?

We have 5 days until #RNA LEADERS EUROPE in Switzerland!? Hear from a packed lineup of 85+ speakers, each bringing invaluable insights across scientific tracks and themes covering: ??mRNA Vaccine & Therapeutics ?? Delivery ??RNA discovery and Analytics ??Oligo-Based RNA Therapeutics ??Gene and RNA editing ??Next-Gen technologies. Who can you meet in Basel? Download the attendee list - ?? https://lnkd.in/efMgyYmy Don't miss your last chance to book your place.?Register here - ??https://lnkd.in/evq5uCb2 #RNALEADERS #BIOTECH #RNA #RNAtherapeutics #mRNA #tRNA #Oligo #tissuetargeting

?? RNA Leaders Industry News?? ? EnPlusOne Biosciences have raised $10M in additional funding to continue to drive development of enzymatic RNA synthesis platform. ??https://lnkd.in/e9Wk5Z92 ? Phase 1 testing of BioNTech SE and Genentech's mRNA-based vaccine, autogene cevumeran, in pancreatic cancer patients demonstrates an vaccine-induced immune response which reduces the risk of recurrent cancer after a three-year follow up. ?? https://lnkd.in/gNwiJRc4 ? Researchers from the Sydney Infectious Diseases Institute, Centenary Institute and Monash Institute of Pharmaceutical Sciences demonstrate potential of a novel LNP-mRNA vaccine against tuberculosis. ?? https://lnkd.in/eMSdfVN7 ?University of Chinese Academy of Sciences researchers leverage human H-ferritin engineered nanocarriers to facilitate siRNA escape from lysosomes in RNAi therapy in glioblastoma. ?? https://lnkd.in/eZ3pjE_9 Join us in person in under 2 weeks time at RNA Leaders Europe, to hear more exciting industry updates!.. ?? Andrea-Clemencia Pineda-Pe?a, Sanofi - Exploring the optimizing of mRNA-based vaccine clinical candidates through an integrated iterative translational science framework. ?? Alexander Zehnder, MD, MBA, CureVac - Sharing insights on accelerating innovation and commercialisation of RNA-based therapeutics and vaccines ?? Sophia Lugo, Radar Therapeutics - Exploring in vivo precisely expressed mRNA therapeutics leveraging ADAR-editing ?? Paul Nioi, Alnylam Pharmaceuticals - Discussing phase 3 study of vutrisiran to treat cardiomyopathy - results and regulatory pathway ?? Confirm your place today here: https://lnkd.in/d5j_TVPj #RNALeaders #RNAi #mRNA #oligonucleotides #vaccines

I will be speaking at RNA Leaders Europe, on 4 - 6 March 2025. https://lnkd.in/eA9QpnM9 . Join me as we accelerate innovation and commercialisation of #RNA therapeutics and vaccines #RNALeaders #RNALeadersEU25. Please also contact me to discuss partnering Ribocures siRNA platforms and programs. Informa Connect

?????????? ???????????????????????? – ?????? ?????????????? ????????????! What partnerships have aided the development of RNA Therapeutics, and what does it take to maintain these complex relationships? RNA Leaders Congress Europe 2025 delves into this and so much more in less than two weeks! This session will cover: ??Highlighting successful partnerships that have driven innovation and accelerated the development of RNA-based drugs ??Discussing the challenges and opportunities associated with forming and maintaining effective collaborations in the complex and rapidly evolving RNA therapeutics market ??Exploring the disease areas beyond infectious diseases such as neurological, cardiovascular, respiratory and rare diseases where RNA therapeutics advancements provide new opportunities for Pharma Download the agenda to see the full agenda -https://lnkd.in/e6-EqS5N &utm_campaign=rnaeu25 Our final early bird discount expires Friday 21st February, so register today to be a part of this must-attend gathering of senior RNA executives. Click here to secure your discount: https://lnkd.in/evq5uCb2 Find out more about RNA Leaders Europe Congress - https://lnkd.in/d9upXH2t Panel features: Renee T. Williams, PhD MBA, Founder and Managing Partner at Williams Biotech Consulting, LLC John D. Taylor, Global Head of Business Development at RiboCure Ulrik Lytt Rahbek, VP of Partnerships RNA and Gene Therapies at Novo Nordisk Malgorzata Gonciarz, Global Head xRNA Therapeutics at Novartis Alexander Zehnder, MD, MBA, CEO, CureVac #rnaleaders #rna #rnatherapeutics #biotech #switzerland #rnaevent #pharma #rarediseases ?

The first RNA Leaders Congress of the year is 2 weeks away! Industry leaders like Johnson & Johnson, Alnylam, Lonza, Eli Lilly, Apollo Ventures, Moderna & Sanofi are already lining up meetings to forge strategic alliances, share insights, and tackle some of the biggest challenges in RNA therapeutics. Who can you meet in Basel? Download the attendee list - ?? https://lnkd.in/efMgyYmy Time is running out: Final early bird tickets close this Friday. If you want to be in the room with the most influential minds in RNA, this is your last chance! Register here - ??https://lnkd.in/evq5uCb2 #RNALEADERS #BIOTECH #RNA #RNAtherapeutics #mRNA #tRNA #Oligo #tissuetargeting

??RNA Leaders Industry News?? ? The European Commission have approved the first ever self-amplifying mRNA vaccine for COVID-19 developed by Arcturus Therapeutics and CSL ??https://lnkd.in/dqinSB7F ?Congratulations to HAYA Therapeutics, who have been awarded Innosuisse certificate for sustainable growth and 1.5M CHF funding to progress lncRNA-based therapies for aggressive solid tumors ??https://lnkd.in/dCRzE_eu ?Terrain Biosciences have launched from stealth mode, to enable faster development of RNA-based therapeutics and vaccines using novel AI models and its proprietary manufacturing platform. ??https://lnkd.in/dr7FqU6S ?Researchers at UCL and UK Dementia Research Institute show reduced somatic CAG repeat expansion in Huntington's disease iPSC-derived striatal neurons when treated with an MSH3-targetting ASO. ??https://lnkd.in/dPpC__TF ?Aro Biotherapeutics appoints Purnanand Sarma as CEO ??https://lnkd.in/dDk7EFfU Join our next in-person meeting this 4-6th March in Basel to hear more exciting updates!.. ??Nicola Guzzi, AstraZeneca - Sharing insights on promoting efficacy and safety of oligonucleotide therapeutics through transcriptomics profiling ??Simone Carneiro, Ludwig-Maximilians-Universit?t München - Discussing innovation in mRNA therapeutic dosing and administration ??Lawrence Thompson, Pfizer - Exploring development and qualification of a platform method, for identity and multivalent ratio testing of mRNA products ??Ewen Cameron, Sail Biomedicines - Discussing the AI-based creation of Endless RNA and programmable natural nanoparticles ?? View the full RNA Leaders Europe 2025 program here: https://lnkd.in/eZMZD47y #RNALeaders #RNA #lncRNA #ASO

?????????????? ????????????????: ?????????? ???? ??????! At RNA Leaders Europe Congress 2025, we’re celebrating the incredible women driving innovation in RNA! From groundbreaking research to transformative therapeutics, these leaders are shaping the future of the field—and they’re ready to share their insights. Join us at the Women in RNA Networking Breakfast, where speakers will discuss their journeys in the RNA space, the latest breakthroughs, and the opportunities ahead. A huge thank you to all the women and allies advancing RNA research and therapeutics. LAST CHANCE: Exclusive Discount! With partnering now live, we’re offering a special 10% discount—but act fast, this offer expires TODAY! Claim your discount now: https://lnkd.in/dE2gxh_7 Find out more about RNA Leaders Europe Congress: https://lnkd.in/d9upXH2t #WomenInRNA #RNALeaders #RNAresearch #Biotech #RNAtherapeutics #Networking #WomenInScience #RNA Tamar Grossman, CEO, La Jolla Labs Inc. Renee T. Williams, PhD MBA, Managing Partner, Williams Biotech Consulting, LLC Paola Pozzi, Partner, Sofinnova Telethon Fund, Sofinnova Partners? Malgorzata Gonciarz, Global Head xRNA Therapeutics, Novartis Jenny van Asbeck-van der Wijst, CEO, Mercurna Dr. Myriam Mendila, CSO, CureVac Shalini Andersson, Vice President RNA Gene Cell Therapy at Discovery Sciences,?AstraZeneca? Kemi Olugemo, MD, FAAN, CMO, Korro Bio, Inc.